Literature DB >> 2639730

Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line.

S R Hull1, A Bright, K L Carraway, M Abe, D F Hayes, D W Kufe.   

Abstract

The murine monoclonal antibody DF3, prepared against a membrane-enriched fraction of a human breast carcinoma, recognized high molecular weight mucin-like glycoproteins from normal human milk and breast carcinoma cell lines. Although the epitope recognized appeared to be a peptide segment, recognition was altered by neuraminidase, suggesting carbohydrate contributions to antigen recognition. Examination of DF3 antigen isolated from normal human milk and the BT-20 human breast carcinoma cell line showed significant oligosaccharide differences. DF3 antigen from BT-20 cells contained three major oligosaccharides, the peanut agglutinin-binding disaccharide Gal beta 1,3GalNAc, which is the carbohydrate component of the Thomsen-Friedenreich antigen, and its mono-(NeuAc2,3Gal beta 1,3GalNAc and/or Gal beta 1,3(NeuAc alpha 2,6)GalNAc) and disialylated (NeuAc2,3Gal beta 1,3(NeuAc alpha 2,6)GalNAc) derivatives. In contrast, the DF3 antigen from normal human milk contained the tetrasaccharide Gal beta 1,4GlcNASc beta 1,6(Gal beta 1,3)GalNAc as its major neutral oligosaccharide and also sialylated derivatives of the tetrasaccharide, including a monosialo derivative (Gal beta 1,4GlcNac beta 1,6(NeuAc alpha 2,3Gal beta 2,3)GalNAc and/or NeuAc alpha 2,3Gal beta 1,4GlcNAc beta 1,6 (Gal beta 1,3)GalNAc). These results suggest the possibility of carcinoma-associated alterations in O-linked oligosacchardes of cell surface sialomucins and in the activity of the beta 1,6-glucosaminyl transferase involved in mucin biosynthesis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2639730

Source DB:  PubMed          Journal:  Cancer Commun        ISSN: 0955-3541


  32 in total

Review 1.  L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review.

Authors:  Wenjie Xia; Jie Wang; Youtao Xu; Feng Jiang; Lin Xu
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration.

Authors:  Isabel Correa; Tim Plunkett; Anda Vlad; Arron Mungul; Jessica Candelora-Kettel; Joy M Burchell; Joyce Taylor-Papadimitriou; Olivera J Finn
Journal:  Immunology       Date:  2003-01       Impact factor: 7.397

Review 3.  Sialyltransferases in cancer.

Authors:  F Dall'Olio; M Chiricolo
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

Review 4.  A Believer's Overview of Cancer Immunosurveillance and Immunotherapy.

Authors:  Olivera J Finn
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 5.  Mucin glycoproteins in neoplasia.

Authors:  Y S Kim; J Gum; I Brockhausen
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

6.  Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells.

Authors:  J Gong; D Chen; M Kashiwaba; Y Li; L Chen; H Takeuchi; H Qu; G J Rowse; S J Gendler; D Kufe
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

7.  Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells.

Authors:  J Gong; V Apostolopoulos; D Chen; H Chen; S Koido; S J Gendler; I F McKenzie; D Kufe
Journal:  Immunology       Date:  2000-11       Impact factor: 7.397

8.  Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin.

Authors:  D Nath; A Hartnell; L Happerfield; D W Miles; J Burchell; J Taylor-Papadimitriou; P R Crocker
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

9.  Epitope expression on the breast epithelial mucin.

Authors:  R L Ceriani; J A Peterson; E W Blank; D T Lamport
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

10.  Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells.

Authors:  Dongshu Chen; Jianchuan Xia; Yasuhiro Tanaka; Hongsong Chen; Shigeo Koido; Oliver Wernet; Pinku Mukherjee; Sandra J Gendler; Donald Kufe; Jianlin Gong
Journal:  Immunology       Date:  2003-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.